RxDoctor Payments Data

George Philip, MD

Interventional Cardiology · Boaz, ALNPI 1326284902

Payments from drug & device makers

$4,844in general payments, 2019–2025

Across 269 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$963
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$918
  • Amgen$877
  • Pfizer$389
  • Johnson & Johnson$308
  • Sanofi-aventis U.S. LLC$203
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$4,70897%
  • Education$1363%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,844 in reported general payments places this provider in the 30th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$132,533
Medicare patients
908
Services billed
2,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban725$656,210
FarxigaDapagliflozin Propanediol338$250,451
EntrestoSacubitril/Valsartan243$205,926
Repatha SureclickEvolocumab263$163,309
XareltoRivaroxaban120$118,017
JardianceEmpagliflozin76$62,855
BrilintaTicagrelor98$55,430
MultaqDronedarone Hcl49$52,454
Ranolazine ErRanolazine415$27,692
Metoprolol Succinate1,395$21,147
Repatha SyringeEvolocumab16$14,133
Rosuvastatin Calcium659$11,654
Praluent PenAlirocumab15$10,314
Prasugrel Hcl84$8,151
Atorvastatin Calcium513$7,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$389$656,210725 claims
AstraZenecaFarxiga, Brilinta$190$305,881436 claims
NovartisEntresto$963$205,926243 claims
Johnson & JohnsonXarelto$308$118,017120 claims
Boehringer IngelheimJardiance$17$62,85576 claims
Sanofi-aventis U.S. LLCMultaq$203$52,45449 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →